NCI | Technology Transfer

HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST LMP2

Read more about HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST LMP2

US Application 63/032,954
Filed on 2020-06-01

HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION

Read more about HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION

US Application 63/050,931
Filed on 2020-07-13

A Vaccine Consisting Of Whole Tumor Cells (WTC) Integrated With Amphiphilic Immunogenic Components (AIC) Enhances Antitumor immunity And Augments Tumor Infiltrating Lymphocytes For Adoptive Transfer Therapies.

Read more about A Vaccine Consisting Of Whole Tumor Cells (WTC) Integrated With Amphiphilic Immunogenic Components (AIC) Enhances Antitumor immunity And Augments Tumor Infiltrating Lymphocytes For Adoptive Transfer Therapies.

US Application 62/946,934
Filed on 2019-12-11

HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20

Read more about HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20

US Application 63/043,520
Filed on 2020-06-24

SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM

Read more about SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM

US Application 63/037,058
Filed on 2020-06-10

Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development

Read more about Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development

European Patent
18856142.7
Filed on 2018-09-14

IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS

Read more about IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS

US Application 63/065,388
Filed on 2020-08-13

Fully Human Antibody Targeting Human CD123 For Cancer Threpeutics Development

Read more about Fully Human Antibody Targeting Human CD123 For Cancer Threpeutics Development

US Application 62/734,106
Filed on 2018-09-20

HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST LMP2

Read more about HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST LMP2

US Application 63/008,949
Filed on 2020-04-13

Methods and Compositions For Promoting An Immune Response and For Combination Therapy

Read more about Methods and Compositions For Promoting An Immune Response and For Combination Therapy

US Application 62/908,759
Filed on 2019-10-01

Subscribe to NCI